BioCardia, Inc. (BCDA) SEC filings

BCDANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 5/30

$0.92−0.01 (-0.91%)

Close on Nov 11, 2026Market cap $13.95MP/E –Yield –

SEC filings

40 of BioCardia's most recent filings on SEC EDGAR

Document	Form	Period	Filed	Source
Current report	8-K	Nov 12, 2026	Nov 12, 2026	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2026	Nov 12, 2026	SEC EDGAR
Current report	8-K	Nov 6, 2026	Nov 6, 2026	SEC EDGAR
Current report	8-K	Oct 19, 2026	Oct 19, 2026	SEC EDGAR
Current report	8-K	Oct 7, 2026	Oct 7, 2026	SEC EDGAR
Current report	8-K	Oct 1, 2026	Oct 1, 2026	SEC EDGAR
Current report	8-K	Sep 23, 2026	Sep 23, 2026	SEC EDGAR
Current report	8-K	Sep 21, 2026	Sep 21, 2026	SEC EDGAR
Current report	8-K	Sep 10, 2026	Sep 10, 2026	SEC EDGAR
Current report	8-K	Aug 24, 2026	Aug 24, 2026	SEC EDGAR
Current report	8-K	Aug 19, 2026	Aug 21, 2026	SEC EDGAR
Current report	8-K	Aug 12, 2026	Aug 12, 2026	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2026	Aug 12, 2026	SEC EDGAR
Current report	8-K	Jun 18, 2026	Jun 18, 2026	SEC EDGAR
Current report	8-K	Jun 12, 2026	Jun 12, 2026	SEC EDGAR
Current report	8-K	Jun 8, 2026	Jun 8, 2026	SEC EDGAR
Current report	8-K	Jun 5, 2026	Jun 5, 2026	SEC EDGAR
Current report	8-K	May 28, 2026	May 28, 2026	SEC EDGAR
Current report	8-K	May 21, 2026	May 21, 2026	SEC EDGAR
Current report	8-K	May 15, 2026	May 15, 2026	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2026	May 15, 2026	SEC EDGAR
Current report	8-K	May 8, 2026	May 8, 2026	SEC EDGAR
Current report	8-K	Apr 28, 2026	Apr 28, 2026	SEC EDGAR
Current report	8-K	Apr 20, 2026	Apr 20, 2026	SEC EDGAR
Current report	8-K	Apr 10, 2026	Apr 15, 2026	SEC EDGAR
Current report	8-K	Apr 2, 2026	Apr 2, 2026	SEC EDGAR
Current report	8-K	Mar 24, 2026	Mar 24, 2026	SEC EDGAR
Annual report	10-K	Dec 31, 2025	Mar 24, 2026	SEC EDGAR
Current report	8-K	Mar 17, 2026	Mar 17, 2026	SEC EDGAR
Current report	8-K	Mar 3, 2026	Mar 3, 2026	SEC EDGAR
Current report	8-K	Feb 10, 2026	Feb 10, 2026	SEC EDGAR
Current report	8-K	Feb 3, 2026	Feb 3, 2026	SEC EDGAR
Current report	8-K	Dec 16, 2025	Dec 16, 2025	SEC EDGAR
Current report	8-K	Dec 2, 2025	Dec 3, 2025	SEC EDGAR
Current report	8-K	Nov 24, 2025	Nov 24, 2025	SEC EDGAR
Current report	8-K	Nov 12, 2025	Nov 12, 2025	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2025	Nov 12, 2025	SEC EDGAR
Current report	8-K	Nov 10, 2025	Nov 10, 2025	SEC EDGAR
Proxy statement	DEF 14A	Dec 2, 2025	Nov 3, 2025	SEC EDGAR
Current report	8-K	Oct 30, 2025	Oct 30, 2025	SEC EDGAR

Where these numbers come from

Parsed from the XBRL in BioCardia's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-15 reverse split on May 30, 2024
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is BCDA.

Compare: BCDA vs CELZ · BCDA vs ALLO · BCDA vs SNTI · BCDA vs TLPH · BCDA vs TCRT

Revenue growth-100.0% · median -50.0%

Company	Revenue	Growth
CELZ	$3.00K	-50.0%
TCRT	$3.00K	-50.0%
BCDA	$0	-100.0%
ALLO	–	–
SNTI	–	–
TLPH	$0	-100.0%

Company

Exchange: Nasdaq
Industry: Biological Products, (No Diagnostic Substances)
Fiscal year ends: December 31
Employees: 21
Held by institutions: 8.8%
Auditor: PKF San Diego, LLP
SEC CIK: 925741

Advertisement
300 × 250

See a number that looks wrong?